Research and experimental development on natural sciences and engineering
KEIMON MEDICAL AS
Revenue 2025
NOK 500,000
Operating profit
NOK −1.8m
Equity
NOK −1.3m
Incorporated
2022
Share capital
NOK 100,000
Roles
Daglig lederDaniel Fossum Bratbak
Regnskapsfører
Styrets lederJoseph Oliver Mason
StyremedlemDaniel Fossum Bratbak
Shareholders
| Name | Stake | Shares | Year |
|---|---|---|---|
| BRATBAK CONSULTING AS | 72.0% | 7200.000000 | 2025 |
| TRONVIK CONSULTING AS | 9.0% | 900.000000 | 2025 |
| COMBRA INVEST AS | 7.5% | 750.000000 | 2025 |
| WERGELAND NEUROCONSULTING AS | 5.0% | 495.000000 | 2025 |
| NILY INVEST AS | 2.5% | 250.000000 | 2025 |
| BARRACUDA INVEST AS | 2.2% | 225.000000 | 2025 |
| IRINA ASCHEHOUG | 1.8% | 180.000000 | 2025 |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.